Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
Median Follow-up of 55.6 months – Checkmate 9ER Data
Renal Cell Carcinoma
File
3 pages
Early efficacy with sustained long-term overall survival vs sunitinib: At a median follow-up of 55.6 months (48.1 months minimum), CheckMate 9ER data for Cabozantinib + nivolumab demonstrate a 10.5-month longer mOS vs sunitinib.
CBZ-UK-000343 | November 2024
